Karyopharm Therapeutics | Ventas





Ventas Cambio Fecha
AbbVie USD 16.62B 840M 2025-12
Abbott USD 11.46B 90M 2025-12
Amgen USD 9.9B 340M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
BioCryst Pharmaceuticals USD -86.95M 204.03M 2024-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
Incyte USD 1.51B 140M 2025-12
J&J USD 24.6B 610M 2025-12
Karyopharm Therapeutics USD 30.54M 8.24M 2024-12
MacroGenics USD 72.84M 50.6M 2025-09
Merck USD 16.4B 880M 2025-12
Nektar Therapeutics USD 24.12M 635K 2024-09
Novartis USD 13.91B 144M 2025-09
Novartis USD 14.36B 478M 2025-09
Pfizer USD 17.58B 880M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Takeda JPY 1.19T 80B 2025-12
Tectonic Therapeutic USD 0 0 2024-12
TG Therapeutics USD 161.7M 20.6M 2025-09
Ultragenyx Pharmaceutical USD 160M 6.5M 2025-09
Xencor USD 21M 22.61M 2025-09


Karyopharm Therapeutics Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Feb 2026.